









Joint EMN-HARMONY session:

Data-driven research in Multiple Myeloma

Program overview

Introduction and Chair: Pieter Sonneveld

EMN, EHA SWG on Multiple Myeloma, HARMONY Alliance Partner & Foundation Advisory Board Member

Early disease progression and long-term survival

Elias K. Mai

Heidelberg University Hospital HARMONY Alliance Partner

Enhancing Multiple Myeloma Risk Stratification through Machine Learning Integration

Adrián Mosquera Orqueira

University Hospital of Santiago de Compostela HARMONY Alliance Partner

Synthetic data for accelerating translational research and clinical application

Gastone Castellani

University of Bologna HARMONY Alliance Partner

2





European Public-Private Partnership for big data in hematology

Leverage big data to accelerate blood cancer research



Community of 500+ experts: 128 Partners, including Academic Institutions, medical associations, HTA agencies, regulators, data scientists, Patient Organizations and Pharma Companies.



Data Providers from 34 countries



33+ Collaborative research projects addressing key research questions.

Numerous multi-stakeholder, communications and dissemination projects.





EU funding: 2017 - 2024









Data-driven research infrastructure: robust Big Data Platform, GDPR-compliant data life cycle, integrated data services, visualization and prediction tools.



Data lake 179,000+ data sets AML, ALL, APL, CLL, CML, MDS, MM, MPN, NHL, HL, WM. Open for all blood cancers.



+100 Databases harmonized to OMOP common data model



New legal status in 2024: non-profit research foundation. Transition phase for governance, staffing, operations and agreements.





The importance of continued data-driven collaborations to further transform clinical and scientific research

Goal

 Offer the largest globally available and continuously updated datalake in hematologic malignancies capturing high quality clinical data (including therapeutic response), molecular data, genomic data as well as real world evidence, in a harmonized and GDPR compliant manner.

Value proposition

- Aim at new indications and regular, prospective data accrual
- Define new and precise stratification tools
- Enable personalized treatments and better outcomes for the patients
- Generate quasi real-time monitoring of therapy choices in HM across Europe
- Be a self-financing entity to ensure continuous accrual of high-quality and high-density data on HMs

4











